S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis

Multiple sclerosis (MS) therapies modulate T-cell autoimmunity in the central nervous system (CNS) but may exacerbate latent infections. Fingolimod, a nonselective sphingosine-1-phosphate (S1P) receptor agonist that induces sustained lymphopenia and accumulates in the CNS, represents a new treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular pharmacology 2012-02, Vol.81 (2), p.166-174
Hauptverfasser:	Gonzalez-Cabrera, Pedro J, Cahalan, Stuart M, Nguyen, Nhan, Sarkisyan, Gor, Leaf, Nora B, Cameron, Michael D, Kago, Tomoyuki, Rosen, Hugh
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Central Nervous System - metabolism Cytokines - drug effects Disease Models, Animal Encephalomyelitis, Autoimmune, Experimental - drug therapy Fingolimod Hydrochloride Immunosuppressive Agents Indans Lymphopenia - drug therapy Mice Multiple Sclerosis - drug therapy Oxadiazoles Propylene Glycols - therapeutic use Receptors, Lysosphingolipid - agonists Receptors, Lysosphingolipid - metabolism Sphingosine - analogs & derivatives Sphingosine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!